Thesis
With the upcoming Alzheimer’s and Parkinson’s disease conference, I believe that AVXL is positioned for significant movement as they reveal more promising results for their drug, Blarcamesine. Given the strong market potential, I’m considering taking a position in $4 call options to capitalize on this upcoming catalyst.